Valeo Pharma

Valeo Pharma appoints Tamara Close and Didier Leconte to its Board of directors bit.ly/3NsO3Ro

Valeo Pharma announces filing of new drug submission with Health Canada for COVID-19 prn.to/3JbSpvA

Kyle Steiger, pharmaceutical industry veteran, joins Valeo Pharma as Senior Vice-President and Chief Commercial Officer prn.to/3dV9lZw

Valeo Pharma reports second quarter 2022 revenues 80% above Q2-2021 prn.to/3xR7QmT

Valeo to report Q2-2022 results on June 14, 2022 and hold conference call on June 15, 2022 bit.ly/3xwAPfD

Valeo Pharma enters into LOI with PCPA regarding its two innovative asthma therapies, Enerzair Breezhaler and Atectura Breezhaler bit.ly/3mriYzH

Valeo Pharma to report second quarter 2021 results and hold investors conference call/ webcast bit.ly/3j6oFTG

Valeo Pharma announces commercialization of Enerzair Breezhaler and Atectura Breezhaler following product shipments across Canada and initial deployment of national respiratory sales force. bit.ly/3xFOIp0

Valeo Pharma becomes leading player in respiratory diseases following transformational agreement for two innovative asthma treatments. bit.ly/2QIVnhL #valeopharma #novartis #asthma #agreement

Honored to participate in the fight against COVID-19, with “The Hesperidin Coronavirus Study” to be carried out by the Montreal Heart Institute and Ingenew Pharma Institute (“MHI”) to evaluate our product Hesperco™️. Read more: bit.ly/2NAH51m #valeopharma #Covid_19

Excellent news for patients in Quebec with the positive recommendation for inclusion of Redesca™ on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ). Read more: bit.ly/3sPpGC2 #RAMQ #reimbursement #inesss #lmwh #heparin #redesca

It is with great pleasure that we announce a major addition to our senior management team. Mr. @FredericFasano is now Valeo’s new President and COO while Steve Saviuk remains CEO and Vice-Chairman of the Board. Read more: bit.ly/3oZwQS6 #valeopharma #leadership

There is growing evidence and research suggesting that hesperidin may interfere with SARS-CoV-2 infection process and help against Covid-19 viral replication. Learn more bit.ly/3qdlgTn. Press release bit.ly/3sgV647 #hesperidin #covid19research #covid19news

We are extremely pleased to announce the approval from Health Canada for our low molecular weight heparin biosimilar Redesca™. We expect annual peak sales of $30 million with an impact on revenues starting during the first half of 2021. Read more: bit.ly/39WIwQU #vph

We’re excited to announce that Hesperco is now available on the Amazon Canada marketplace. Order today at amzn.to/39fTJLR #valeopharma #valeohealth #vph #hesperidin #COVID19 #immunesystem #amazon #ecommerce

Good news today as we announce the addition of Amikacin to our hospital specialty products portfolio following Health Canada’s approval, plus the start of Ethacrynate Sodium shipments in the United States. Read more: bit.ly/2IpQpT3 #vph #amikacin #ethacrynatesodium

We’re happy to share a link to an article from InvestorIntel written by Frederick Kozak on how Valeo Pharma’s innovative natural health-based product lines are carving their niche in specialty pharmaceuticals. bit.ly/31B8unO #valeopharma #vph

We are very pleased to announce we started shipping our online orders for our immune system support Hesperco capsules, with national retail availability commencing at the end of the month. Order now at hesperco.com Press release: bit.ly/311VabW

Today, we are reporting our results and highlights for Q3 2020. We are well positioned to exit fiscal year 2020 as a profitable EBITDA company. Read more: bit.ly/33dFiEC #valeopharma #vph #vphif #fse #financialresults #ebitdapositive #healthcareinnovationforcanadians

We are pleased to announce that our shares have started trading today on the U.S. OTCQB market under the symbol, VPHIF. Read more: bit.ly/33Umj1a #valeopharma #vphif #healthcareinnovationforcanadians #otcqb #tradingusa